Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

The purpose of this study is to evaluate the safety, immunogenicity, pharmacodynamics, as well as preliminary efficacy of KRAS neoantigen mRNA vaccine (ABO2102) alone and in combination with toripalimab (anti-PD-1 monoclonal antibody) among participants with KRAS-mutated advanced pancreatic cancer and other solid tumors. The trial includes dose escalation (Part I) and dose expansion(Part II) parts.

Trial Details

NCT ID
NCT06577532
Phase
EARLY_PHASE1
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • ABO2102
  • Toripalimab
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • ≥18 years of age at time of informed consent.
  • Participants with histologically and/ or cytologically confirmed advanced solid tumors (such as pancreatic ductal adenocarcinoma, non-small cell lu…
  • Harboring at least one of the targeted KRAS mutants.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0\~2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →